Hiccup For Evotec As Bayer Pulls Plug On Chronic Cough Drug
German Major Discontinuing Development Of Eliapixant
With the future of eliapixant in doubt, Shinogi's sivopixant struggling and a recent FDA rejection for Merck & Co's chronic cough drug gefapixant, Bellus Health's BLU-5937 looks to have emerged as a best-in-class agent in the P2X3 space.
